Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | NPY2R | P49146 | 1/20 | 0.43 |
| ▸ | PPM1B | O75688 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1542810 | 0.78 | RAB9A (0.64) | ALDH1A1MAPTTSHRMEN1KMT2A | |
| SCHEMBL12919546 | 0.77 | ALDH1A1 (0.55) | ALDH1A1MAPTHSP90AA1MAPK1RAB9A | |
| SCHEMBL28714338 | 0.77 | HTT (0.50) | ALDH1A1MAPTHSP90AA1TSHRMEN1 | |
| SCHEMBL378108 | 0.76 | MEN1 (0.50) | ALDH1A1MAPTHSP90AA1TSHRMEN1 | |
| Hydrochloric Acid SCHEMBL2514818 | 0.76 | MEN1 (0.50) | ALDH1A1HSP90AA1TSHRMEN1KMT2A | |
| SCHEMBL382510 | 0.76 | NOS2 (0.51) | ALDH1A1MAPTHSP90AA1TSHRMEN1 | |
| SCHEMBL12042508 | 0.75 | ALDH1A1 (0.52) | ALDH1A1MAPTHSP90AA1TSHRMEN1 | |
| SCHEMBL6379753 | 0.75 | NPY2R (0.52) | ALDH1A1MAPTHSP90AA1TSHRMEN1 | |
| SCHEMBL12893938 | 0.74 | ALDH1A1 (0.52) | ALDH1A1MAPTHSP90AA1MAPK1RAB9A | |
| SCHEMBL771186 | 0.74 | MAPT (0.66) | ALDH1A1MAPTTSHRMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6605618-B2 | Antidiabetic agents; hypoglycemic agents; anticholesterol agents; side effect reduction | WYETH | 2003-08-12 | — | — | US | disclosed |
| US-20030018045-A1 | Heterocyclic beta-3 adrenergic receptor agonists | WYETH (US) | 2003-01-23 | — | — | US | disclosed |
| US-6451814-B1 | SUBSTITUTED 4-((4-AMINO-5-HYDROXYPHENYL)-OXY-)PIPERIDINE ANALOGS; METABOLIC DISORDERS; ANTIDIABETIC AGENTS; ATHERO-SCLEROSIS, GASTROINTESTINAL DISORDERS, GLAUCOMA, NEUROGENETIC INFLAMMATION, OCULAR HYPERTENSION AND FREQUENT URINATION | WYETH | 2002-09-17 | — | — | US | disclosed |
| US-20020028832-A1 | Heterocyclic beta-3 adrenergic receptor agonists | AMERICAN HOME PRODUCTS CORPORATION (US) | 2002-03-07 | — | — | US | disclosed |
| WO-2002006229-A2 | HETEROCYCLIC BETA-3 ADRENERGIC RECEPTOR AGONISTS | WYETH (US) | 2002-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030018045-A1 | Heterocyclic beta-3 adrenergic receptor agonists | ADRB2, ADRB1, ADRB3 | ALDH1A1 725/4885MAPT 1539/4885HSP90AA1 3001/4885 |
| US-20020028832-A1 | Heterocyclic beta-3 adrenergic receptor agonists | ADRB1, ADRB3, ADRB2 | ALDH1A1 524/4885MAPT 1106/4885HSP90AA1 2728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.